Translational Trial Group
The Translational Trial Group of the KiTZ Clinical Trial Unit translates the latest research findings - including results from the preclinical program of the KiTZ - into an innovative treatment concept. This multidisciplinary team of specialized physicians and trial managers, working together closely with the Department of Biostatistics of the DKFZ and the NCT Trial Center, develops innovative international study protocols and coordinates its own phase I-III academic studies with sites in and outside Europe. The main focus is on biomarker driven trials and targeted/immune therapies using new drugs and rationale combinations. Examples of the two main current activities (INFORM2 trial series and the LOGGIC project) can be found below.
The group is embedded in several international networks. ITCC (Innovative Therapy for Children with Cancer) is a network of pediatric phase I/II sites and an important partner for academia and pharmaceutical industry for the roll out of pediatric early phase clinical trials. KiTZ has received ITCC international sponsor and national coordination accreditation in 2018, enabling the Translational Trial Group to roll out its own academic trials over the large ITCC network under its own governance. Furthermore, strong collaborations exist with other clinical trial groups in Germany (Society for Pediatric Oncology and Hematology (GPOH)), Europe, North-America (St. Jude and CONNECT) and Australia. Also, strong collaborations with the pharmaceutical industry guarantee access to new innovative drugs.
Importantly, the Translational Trial Group also builds partnerships with investigators performing clinical trials in adult oncology, e.g. in the NCT.